MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
BioXcel Therapeutics, Inc. (NASDAQ: BTAI)*
Organization & Developments: BioXcel
Parents
BioXcel Therapeutics, Inc. (NASDAQ: BTAI)*
Children
*BioXcel Therapeutics is developing high value therapeutics in neuroscience and immuno-oncology utilizing a novel artificial intelligence platform.
*BioXcel Therapeutics uses artificial intelligence (AI) to develop cutting-edge medicines across neuroscience and immuno-oncology.
*Lead asset, BXCL501 for agitation in schizophrenia and bipolar disorder
2020: BioXcel Therapeutics Has Compelling Upside Potential In Advance Of Multiple Data Readouts
2020: BioXcel Therapeutics: Big Upside Potential
2020: BioXcel: Banking On The 505(B)(2) NDA Pathway
2021: BioXcel Therapeutics: Ready To Enter The Depression Therapeutic Field
2021: Still Betting On BioXcel Therapeutics Stock
2022: Bioxcel Therapeutics: What To Expect From The Upcoming PDFA_seekingalpha.com
2023: BioXcel Therapeutics: Clinical Trial Milestones Drive Stock But Slow Market Adoption Persists
2023: The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO
2024: BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
2024: BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation
Jumps
*Key People: BioXcel
Finance & Acquisition: BioXcel